title: [The place of cardiac glycosides in the treatment of chronic heart failure. Part III. The DIG trial].
abstract: In a series of papers the authors analyze literature data on the use of cardiac glycosides for long term treatment of chronic heart failure. Data obtained in prospective placebo controlled trial DIG show that digoxin significantly increases mortality of all patients with sinus rhythm and intact left ventricular systolic function (ejection fraction > 45%) and of women with left ventricular systolic dysfunction (ejection fraction < or = 45%). Men with left ventricular systolic dysfunction represent the only category of patients with chronic heart failure in sinus rhythm in whom long term administration of digoxin is justified. Digoxin does not affect mortality of these patients however it reduces requirements in hospitalizations due to worsening of heart failure.
authors: B A
authors: BA
authors: Sidorenko
authors: D V
authors: DV
authors: Preobrazhenskiĭ
authors: I A
authors: IA
authors: Sharoshina
authors: T A
authors: TA
authors: Batyraliev
authors: I V
authors: IV
authors: Pershukov
authors: S A
authors: SA
authors: Makhmutkhodzhaev
mesh_terms: D002301:Cardiac Glycosides / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
chemical_list: D002301:Cardiac Glycosides; D002316:Cardiotonic Agents